Assessment of long‐term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy - Concepedia

Concepedia

Publication | Open Access

Assessment of long‐term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy

DOI Full Paper Access

35

Citations

47

References

2015

Year

Selin Merdan, Scott A. Tomlins, Christine Barnett, Todd M. Morgan, James E. Montie, John T. Wei, Brian T. Denton

Abstract

The use of PCA3 or T2:ERG testing for repeat biopsy decisions can substantially reduce the number of biopsies without significantly affecting 10-year survival.

References

	Year	Citations

Page 1